Alnylam raises $387.5M

Just over five months after gaining its first-ever approval of an RNAi therapy, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has raised $387.5 million on Jan. 15 in a follow-on funding intended to build its commercial capabilities.

Alnylam priced 5 million shares at $77.50, an 8% discount to the company's closing price of $84.02 on Jan. 14. The company announced the offering shortly after market close, then priced it hours later Jan. 14. Barclays is the sole underwriter...